Glucomet, combining the active ingredients Metformin and Glibenclamide (also known as Glyburide), is indicated as an adjunct to diet and exercise for the management of Type 2 Diabetes Mellitus (T2DM) in adults. This medication is typically considered when T2DM is not sufficiently managed by diet, exercise, and Metformin alone. The combined formulation is used to help maintain appropriate blood glucose levels and supports overall metabolic stability by assisting with glucose regulation. The key therapeutic uses include: supporting blood sugar balance, and contributing to long-term metabolic control when monotherapy is inadequate.

Quick Fact: Relief for Elevated Blood Glucose

The Metformin/Glibenclamide fixed-dose combination is formally indicated for use only in adults with Type 2 Diabetes Mellitus. Use is not recommended for pediatric patients, as safety and effectiveness have not been established by regulatory authorities. Use in older adults (aged 65 years and older) is permitted, but requires more frequent monitoring of renal function.

Contraindications and Restrictions

This medication is subject to strict exclusions and must not be used in the following populations and conditions, as defined by official regulatory labeling:

These limitations serve to prevent serious complications, such as lactic acidosis, by excluding individuals whose organ function or acute clinical state compromises the metabolism or clearance of the medicine's components.

Interactions with Other Medicines and Products

The interaction profile for Glucomet (Metformin/Glibenclamide) is defined by both pharmacokinetic and pharmacodynamic constraints, as documented in government regulatory labeling. The co-administration of certain substances is formally prohibited due to specific risks.

Formal Regulatory Prohibitions

Oral Miconazole and Bosentan are contraindicated due to the potential for severe hypoglycemia and risk of elevated liver enzymes, respectively. Acute or excessive alcohol intake is strictly prohibited as it is documented to potentiate the Metformin component’s effect on lactate metabolism, dramatically increasing the risk of lactic acidosis.

Pharmacokinetic and Pharmacodynamic Interference

Timing and Procedural Restrictions

The drug must be temporarily discontinued at the time of or prior to procedures utilizing Iodinated Contrast Media or elective major surgery. Administration is withheld for 48 hours subsequent to these procedures until normal kidney function is confirmed. Furthermore, official labeling requires the drug be administered at least 4 hours prior to Colesevelam to prevent reduced absorption. The risk of interaction-related lactic acidosis is also heightened in the elderly population and those with hepatic impairment.

The combination of Metformin and Glibenclamide exerts its effects through two distinct, complementary mechanisms influencing glucose metabolism at the cellular and physiological levels.

Pancreatic KATP Channel Modulation

Glibenclamide, a sulfonylurea, targets the sulfonylurea receptor 1 ( SUR1) subunit of ATP-sensitive potassium ( K ATP) channels on pancreatic beta-cells. Binding to SUR1 closes the K ATP channels, causing cell membrane depolarization. This depolarization activates voltage-gated calcium channels, resulting in a calcium ion influx that triggers the exocytosis of insulin-containing vesicles, leading to the release of stored insulin into the bloodstream.

Inhibition of Hepatic Glucose Output and Cellular Energy Sensing

Metformin, a biguanide, primarily acts within the liver. It decreases the rate of hepatic gluconeogenesis (glucose production by the liver) by inhibiting the mitochondrial respiratory chain. This inhibition leads to the activation of AMP-activated protein kinase (AMPK), which suppresses the transcription of enzymes required for glucose synthesis. This cascade results in a decrease in the basal level of circulating glucose via suppressed hepatic gluconeogenesis. Additionally, Metformin increases glucose uptake and utilization by peripheral tissues through an enhancement of the cellular response to insulin.

The fixed-dose combination of Metformin Hydrochloride and Glibenclamide is administered exclusively via the oral route as a tablet. Treatment involves a process of initiation, titration, and specific frequency. For adult patients, treatment typically begins with the lowest available strength, such as 1.25 mg Glibenclamide/250 mg Metformin HCl, and is administered in divided doses twice daily. The tablet must be taken with meals (e.g., breakfast and dinner) to maximize patient tolerability. Dose adjustment, or titration, is a gradual process undertaken at intervals of no less than two weeks, determined by the patient’s glycemic response. The total daily intake is limited and must not exceed 20 mg Glibenclamide and 2000 mg Metformin HCl.

Administration requires careful consideration of renal function across all patient groups. The drug's use is contraindicated if the estimated Glomerular Filtration Rate (eGFR) falls below 30 mL/minute/1.73 m^2. For older adults, therapy is often initiated with the lowest possible dose, accompanied by continuous monitoring of kidney function. The protocol also includes a required temporary discontinuation: the tablet is withheld at the time of or prior to any radiological procedure involving an iodinated contrast agent and for a period afterward. If a routine dose is missed, it is typically taken as soon as possible, but taking a double dose to compensate for the lapse is strictly prohibited.

Research Evidence Overview

Evidence for Inadequate Control on Monotherapy

Research has explored this combination therapy primarily in adults with Type 2 Diabetes Mellitus (T2DM) whose blood sugar levels were described as inadequately controlled by a single medication, such as Metformin or Glibenclamide, used alone. Studies examining this clinical scenario were typically structured as Randomized Controlled Trials (RCTs), where researchers observed groups receiving the combination therapy against groups continuing with their single drug.

These comparative studies were used in research exploring how blood sugar levels change over time. The primary outcomes monitored were outcomes reflecting functional imbalance, including changes in the blood sugar marker Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG). The findings describe patterns observed in the studies which compared the combination to the use of a single component drug.

Evidence for Use as Initial Therapy

Studies were conducted to research scenarios where the fixed-dose combination was used in adults initiating therapy for T2DM. This research examined patients presenting with cycles of stability and flare-ups, specifically those with more noticeable blood sugar elevations, such as high baseline HbA1c levels.

How Trials Measured Effects

In these trials, the studies monitored the same key outcomes as those for patients switching from monotherapy, including changes in HbA1c and FPG. Studies also monitored outcomes reflecting daily functioning or activity level by measuring the percentage of participants whose blood sugar measurements met a pre-defined study target. Research highlights changes measured during the study period for metabolic markers, including plasma lipid profiles and body weight. These findings help contextualize how patients reported their experience over the course of the trial.

Long-Term Evidence and Follow-Up Data

The available evidence for the fixed-dose combination largely stems from short-term trials. The follow-up durations were limited for many comparative studies, which often only spanned 16 weeks to 6 months. Limited information exists for long-term outcomes regarding the fixed-dose combination itself. Long-term effects are not fully established when it comes to patient-important clinical events, such as cardiovascular outcomes (e.g., heart attack or stroke), or whether a sustained metabolic pattern is observed over many years.

Common questions about Glucomet (+Glibenclamide) (FAQ)

Q: What should I do if I miss a dose of this medication?

If a dose is missed, it is generally advised to take it as soon as you remember, unless it is close to the time for your next scheduled dose. In that case, you may skip the missed dose and resume your regular dosing schedule. Do not take a double dose to make up for the missed one, as this increases the potential risk of low blood sugar (hypoglycemia). Consult with a healthcare provider for personalized advice on managing missed doses.

Q: Does this medication cause weight gain?

The component metformin is generally associated with either stable weight or a modest weight reduction in some individuals. The component glibenclamide, however, belongs to a class of medicines (sulfonylureas) that may be associated with weight gain. The effect on an individual's weight can vary. Discuss any concerns about weight changes with a healthcare provider.

Q: Can I drink alcohol while taking this combination medicine?

The product information generally advises caution or avoidance of alcohol use. Drinking excessive amounts of alcohol, especially if you are fasting or malnourished, can increase the risk of developing a serious condition called lactic acidosis, which is a rare but severe side effect associated with metformin. Alcohol can also increase the risk of low blood sugar (hypoglycemia) due to the glibenclamide component. Always consult with your healthcare provider regarding alcohol consumption.

Q: How often will my blood sugar levels need to be checked while on this drug?

Monitoring blood sugar levels is a key part of managing diabetes. Your healthcare provider will determine the appropriate frequency and method of monitoring for you, which typically includes regular A1C tests and self-monitoring of blood glucose. The required frequency can change based on your specific treatment goals and overall health status.

Storage and Disposal Requirements for Metformin and Glibenclamide

Official Storage Conditions

Metformin and Glibenclamide tablets must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with permitted excursions to 15 C to 30 C (59 F to 86 F). The product must be stored away from heat, moisture, and direct light, and must not be frozen.

Handling and Safety

Keep the medicine in its original, closed container and ensure the cap or pack is tightly closed. As a mandatory safety rule, keep this product, and all medicines, out of the sight and reach of children.

Disposal

Do not keep outdated medicine or medicine no longer needed. Unused or expired tablets must be disposed of in accordance with local requirements. Consult a healthcare professional on how to safely dispose of any medicine you do not use.